

BIOCON GROUP

FACT SHEET

Sep - 2022

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q2'FY 23	Q2'FY 22	Variance %
<u>INCOME</u>			
Generics	623	530	18%
Biosimilars	997	743	34%
Novel Biologics	-	12	-100%
Research services	768	610	26%
Inter-segment	(69)	(54)	26%
Revenue from operations #	2,320	1,840	26%
Other income	65	105	-39%
TOTAL REVENUE	2,384	1,945	23%
<u>EXPENDITURE</u>			
Material & Power costs	850	641	33%
Staff costs	492	437	13%
Research & Development expenses*	242	146	65%
Other expenses	265	170	55%
Manufacturing, staff & other expenses	1,849	1,395	33%
EBITDA	535	551	-3%
Interest & Finance charges	30	23	33%
Depreciation & Amortisation	231	202	15%
Share of loss / (profit) in JV / Associate, net	28	51	-44%
PBT	246	276	-11%
Exceptional item	(17)	(70)	-
PBT	229	206	11%
Taxes	43	59	-27%
Tax expense on adoption of new tax regime	107	-	100%
Taxes on exceptional item	(2)	(12)	-81%
NET PROFIT BEFORE MINORITY INTEREST	82	160	-49%
Minority interest	35	29	20%
Minority interest on exceptional item	(0)	(8)	-96%
NET PROFIT FOR THE PERIOD	47	138	-66%
EPS Rs.	0.4	1.2	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	168	188	-10%
Exceptional item, net of taxes	(14)	(50)	-71%
Tax expense on adoption of new tax regime	(107)	-	100%
NET PROFIT FOR THE PERIOD	47	138	-66%
<i># Licensing Income</i>	10	13	
<i>* Gross Research & Development expenses</i>	252	165	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	Q2' FY 23	Q1' FY 23	Variance %
INCOME			
Generics	623	580	7%
Biosimilars	997	977	2%
Novel Biologics	-	-	100%
Research services	768	645	19%
Inter-segment	(69)	(61)	12%
Revenue from operations #	2,320	2,140	8%
Other income	65	78	-17%
TOTAL REVENUE	2,384	2,217	8%
EXPENDITURE			
Material & Power costs	850	795	7%
Staff costs	492	463	6%
Research & Development expenses*	242	198	22%
Other expenses	265	285	-7%
Manufacturing, staff & other expenses	1,849	1,740	6%
EBITDA	535	478	12%
Interest & Finance charges	30	20	47%
Depreciation & Amortisation	231	217	6%
Share of loss / (profit) in JV / Associate, net	28	43	100%
PBT BEFORE EXCEPTIONAL ITEM	246	197	25%
Exceptional item, Net	(17)	-	-100%
PBT	229	197	16%
Taxes	43	30	44%
Tax expense on adoption of new tax regime	107	-	100%
Taxes on exceptional item	(2)	-	0%
NET PROFIT BEFORE MINORITY INTEREST	82	167	-51%
Minority interest	35	23	53%
Minority interest on exceptional item	(0)	-	-
NET PROFIT FOR THE PERIOD	47	144	-67%
EPS Rs.	0.4	1.2	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
Exceptional item	(14)	-	
Tax expense on adoption of new tax regime	(107)	-	
NET PROFIT FOR THE PERIOD	47	144	-67%
<i># Licensing Income</i>	<i>10</i>	<i>9</i>	
<i>* Gross Research & Development expenses</i>	<i>252</i>	<i>223</i>	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	H1' FY 23	H1' FY 22	Variance %
<u>INCOME</u>			
Generics	1,203	1,016	18%
Biosimilars	1,974	1,501	32%
Novel Biologics	-	23	-
Research services	1,413	1,205	17%
Inter-segment	(130)	(144)	-10%
Revenue from operations #	4,459	3,601	24%
Other income	142	152	-6%
TOTAL REVENUE	4,602	3,753	23%
<u>EXPENDITURE</u>			
Material & Power costs	1,645	1,327	24%
Staff costs	955	832	15%
Research & Development expenses*	440	266	65%
Other expenses	549	342	61%
Manufacturing, staff & other expenses	3,589	2,766	30%
EBITDA	1,013	987	3%
Interest & Finance charges	50	42	19%
Depreciation & Amortisation	448	396	13%
Share of loss / (profit) in JV / Associate, net	71	107	100%
PBT BEFORE EXCEPTIONAL ITEM	443	442	0%
Exceptional item, Net	(17)	(70)	-
PBT	426	372	15%
Taxes	72	116	-38%
Tax expense on adoption of new tax regime	107	-	
Taxes on exceptional item	(2)	(12)	-971%
NET PROFIT BEFORE MINORITY INTEREST	249	268	-7%
Minority interest	58	53	9%
Minority interest on exceptional item	(0)	(8)	-
NET PROFIT FOR THE PERIOD	191	223	-14%
EPS Rs.	1.6	2.5	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	313	273	15%
Exceptional item, net of taxes	(14)	(50)	-71%
Tax expense on adoption of new tax regime	(107)	-	
NET PROFIT FOR THE PERIOD	191	223	-14%
<i># Licensing Income</i>	19	22	
<i>* Gross Research & Development expenses</i>	475	301	

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Crores)

Particulars	September 30, 2022	March 31, 2022
ASSETS		
Non-current assets		
(a) Property, plant and equipment	7,171	5,677
(b) Capital work-in-progress	2,275	3,420
(c) Right-of-use assets	263	267
(d) Goodwill	26	26
(e) Other intangible assets	574	599
(f) Intangible assets under development	764	690
(g) Investment in associates and a joint venture	98	8
(h) Financial assets	-	-
Investments	256	362
Derivative assets	175	147
Other financial assets	117	45
(i) Income tax asset, net	369	314
(j) Deferred tax asset, net	305	293
(k) Other non-current assets	222	163
Non-current assets	12,615	12,012
Current assets		
(a) Inventories	2,982	2,298
(b) Financial assets		
Investments	2,500	1,218
Trade receivables	2,079	2,058
Cash and cash equivalents	751	663
Other bank balances	727	1,085
Derivative assets	51	122
Loans and advances	-	67
Other financial assets	480	451
(c) Other current assets	479	421
Current assets	10,049	8,382
TOTAL - ASSETS	22,664	20,394
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	600	600
(b) Other equity	9,028	7,832
Equity attributable to owners of the Company	9,628	8,433
Non-controlling interests	1,212	1,038
Total Equity	10,840	9,470
Non-current liabilities		
(a) Financial liabilities		
Borrowings	4,438	3,999
Lease liabilities	194	222
Derivative liabilities	69	14
Other financial liabilities	1,506	1,503
(b) Provisions	98	92
(c) Deferred tax liability, net	72	52
(d) Other non-current liabilities	1,321	1,215
Non-current liabilities	7,698	7,096
Current liabilities		
(a) Financial liabilities		
Borrowings	1,178	906
Lease liabilities	51	21
Trade payables	1,699	1,609
Derivative liabilities	121	12
Other financial liabilities	279	363
(b) Provisions	146	131
(c) Income tax liability, net	231	162
(d) Other current liabilities	421	625
Current liabilities	4,126	3,828
TOTAL - EQUITY AND LIABILITIES	22,664	20,394